• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Vaxcyte (PCVX) Is Up 8.9% After Completing VAX-31 Phase 3 Enrollment Amid Rising Losses – Has The Bull Case Changed?

    Simply Wall St·08/07/2026 07:29:37
    Listen to the news
    • In early August 2026, Vaxcyte reported a second-quarter net loss of US$284.3 million and higher per-share losses, while also updating investors on its vaccine pipeline.
    • The company’s completion of enrollment across three adult Phase 3 OPUS trials for VAX-31, alongside the first-in-human VAX-A1 study, underscores a rapid build-out of late- and early-stage programs despite rising costs.
    • Next, we’ll examine how completing enrollment in the three VAX-31 Phase 3 OPUS trials could reshape Vaxcyte’s existing investment narrative.

    The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    Vaxcyte Investment Narrative Recap

    To own Vaxcyte today, you need to believe that VAX-31 can emerge from the OPUS Phase 3 program with data strong enough to support approval and real-world uptake, while the company manages rising losses without exhausting its cash runway. The latest results, including a Q2 net loss of US$284.3 million and higher per-share losses, do not change the near term focus: OPUS-1 adult data remains the key catalyst, with funding needs the most immediate risk.

    Among the recent updates, the completion of enrollment across all three adult Phase 3 OPUS trials for VAX-31 looks most relevant. With 6,191 adults dosed and a manufacturing consistency study planned to complete the biologics license application package, Vaxcyte has now locked in the clinical dataset that will underpin its first potential commercial filing. That progress sits alongside the VAX-A1 first in human study, which could become a secondary driver if Group A Strep data support further development.

    Yet despite this progress, the combination of rising net losses and a finite cash runway is a risk investors should be aware of if...

    Read the full narrative on Vaxcyte (it's free!)

    Vaxcyte’s narrative projects $224.6 million revenue and $28.1 million earnings by 2029. This implies an earnings increase of about $795 million from -$766.6 million today.

    Uncover how Vaxcyte's forecasts yield a $109.00 fair value, a 85% upside to its current price.

    Exploring Other Perspectives

    PCVX 1-Year Stock Price Chart
    PCVX 1-Year Stock Price Chart

    Some of the most optimistic analysts, who once modeled revenue reaching about US$423.8 million by 2029, see OPUS progress and the Lonza manufacturing buildout as unlocking a much larger opportunity than the consensus view, but after such a sharp step up in losses this quarter, you might reasonably question whether those bullish expectations still fit with the cash burn and timelines implied by the latest update.

    Explore 3 other fair value estimates on Vaxcyte - why the stock might be worth over 3x more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Interested In Other Possibilities?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.